AMAG Pharmaceuticals Earnings: Here’s Why the Stock is Down Now

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 1.51%.

The stock market is roaring back in 2013. Click here now to discover winning stocks!

AMAG Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.17 in the quarter versus EPS of $-0.87 in the year-earlier quarter.

Revenue: Rose 41.78% to $21.14 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: AMAG Pharmaceuticals, Inc. reported adjusted EPS loss of $0.17 per share. By that measure, the company missed the mean analyst estimate of $-0.07. It missed the average revenue estimate of $22.54 million.

Quoting Management: “In 2012, we took actions to stabilize our business – such as stopping the historical decline of our average net revenues per gram,” stated William Heiden, president and chief executive officer of AMAG. “We then turned our focus to putting Feraheme on a solid growth trajectory, achieving 12 percent dollar growth for the year, while reducing expenses by more than 30 percent as compared to 2011. Our goals for 2013 are clear, to continue to drive growth of Feraheme while we prepare for the potential launch in the broader IDA indication, expand our product portfolio and continue the disciplined management of our expenses.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business